These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 12575714)

  • 21. Anti-inflammatory efficacy versus gastrointestinal safety: a dilemma resolved? Introduction.
    Bach GL
    Scand J Rheumatol Suppl; 1992; 96():5-6. PubMed ID: 1439625
    [No Abstract]   [Full Text] [Related]  

  • 22. Upper gastrointestinal tolerability of celecoxib, a COX-2 specific inhibitor, compared to naproxen and placebo.
    Bensen WG; Zhao SZ; Burke TA; Zabinski RA; Makuch RW; Maurath CJ; Agrawal NM; Geis GS
    J Rheumatol; 2000 Aug; 27(8):1876-83. PubMed ID: 10955327
    [TBL] [Abstract][Full Text] [Related]  

  • 23. COX-2 inhibitors.
    Brooks PM; Day RO
    Med J Aust; 2000 Oct; 173(8):433-6. PubMed ID: 11090038
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Serious gastrointestinal events from low dose analgesic use.
    Tarone RE; Lipworth L; McLaughlin JK
    J Rheumatol; 2004 May; 31(5):1008-9; author reply 1010-1. PubMed ID: 15124269
    [No Abstract]   [Full Text] [Related]  

  • 25. [Mobility and quality of life for arthrosis and rheumatism patients. Modern pain management with selective cox-2 inhibition].
    MMW Fortschr Med; 2002 Jul; 144(29-30):52. PubMed ID: 12219613
    [No Abstract]   [Full Text] [Related]  

  • 26. NSAIDs questionable as first-line therapy for rheumatic conditions in the elderly.
    Salach RH; Calabrese LH
    J Am Osteopath Assoc; 1994 Sep; 94(9):714, 766. PubMed ID: 7995734
    [No Abstract]   [Full Text] [Related]  

  • 27. [New treatment of pain and fever in rheumatoid arthritis and arthrosis. The first cyclooxygenase-2 inhibitors show promising results].
    Oliw E; Wollheim FA
    Lakartidningen; 2000 Jun; 97(24):2942-4. PubMed ID: 10900877
    [No Abstract]   [Full Text] [Related]  

  • 28. [A critical evaluation of side effect data on COX-2 inhibitors].
    Pomp E
    Tidsskr Nor Laegeforen; 2002 Feb; 122(5):476-80. PubMed ID: 11961974
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Meta-analysis: upper gastrointestinal tolerability of valdecoxib, a cyclooxygenase-2-specific inhibitor, compared with nonspecific nonsteroidal anti-inflammatory drugs among patients with osteoarthritis and rheumatoid arthritis.
    Eisen GM; Goldstein JL; Hanna DB; Rublee DA
    Aliment Pharmacol Ther; 2005 Mar; 21(5):591-8. PubMed ID: 15740543
    [TBL] [Abstract][Full Text] [Related]  

  • 30. New drug overview. Celecoxib.
    Am J Health Syst Pharm; 1999 May; 56(10):1031. PubMed ID: 10365731
    [No Abstract]   [Full Text] [Related]  

  • 31. Persistence with non-selective NSAIDs and celecoxib among patients with gastroesophageal reflux disease and osteoarthritis or rheumatoid arthritis.
    Cryer B; Luo X; Assaf AR; Sands G; Mardekian J
    Curr Med Res Opin; 2011 Feb; 27(2):295-302. PubMed ID: 21142617
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [NSAID therapy. Gastrointestinal risks of classic NSAID are underestimated].
    MMW Fortschr Med; 2010 May; 152(20):46-7. PubMed ID: 20552882
    [No Abstract]   [Full Text] [Related]  

  • 33. Balancing the risks and benefits of celecoxib.
    Caldwell B; Beasley R; Weatherall M; Metcalfe S
    Am J Med; 2007 Jun; 120(6):e17. PubMed ID: 17524734
    [No Abstract]   [Full Text] [Related]  

  • 34. Drug utilization review of celecoxib in Ontario.
    LeLorier J; Fitzsimon C; Keresteci M; Stewart D; Lavoie F
    Rheumatology (Oxford); 2003 Nov; 42 Suppl 3():iii11-6. PubMed ID: 14585913
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Celecoxib for rheumatoid arthritis.
    Megeff CE; Strayer SM
    J Fam Pract; 2000 Feb; 49(2):108-9. PubMed ID: 10718683
    [No Abstract]   [Full Text] [Related]  

  • 36. [Current EULAR data on valdecoxib. New study results of gastrointestinal safety and "cost effectiveness"].
    Kellner H
    Krankenpfl J; 2004; 42(5-6):185. PubMed ID: 15527245
    [No Abstract]   [Full Text] [Related]  

  • 37. Are rofecoxib and celecoxib safer NSAIDS?
    Drug Ther Bull; 2000 Nov; 38(11):81-6. PubMed ID: 11138599
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A regional audit of the use of COX-2 selective non-steroidal anti-inflammatory drugs (NSAIDs) in rheumatology clinics in the West Midlands, in relation to NICE guidelines.
    Price-Forbes AN; Callaghan R; Allen ME; Rowe IF
    Rheumatology (Oxford); 2005 Jul; 44(7):921-4. PubMed ID: 15827035
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [COX-2 inhibitors: a new treatment in rheumatic diseases].
    Puddu G; Cravero E
    Clin Ter; 2003; 154(1):39-43. PubMed ID: 12854282
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Celecoxib-induced upper gastrointestinal hemorrhage and ulceration.
    Crawford AS; White JG
    South Med J; 2002 Dec; 95(12):1444-6. PubMed ID: 12597315
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.